- Physicians and Healthcare Professionals
- Reimbursement and Insurance Coverage
- Patients and Caregivers
- Products and Services
- Ordering Information
The Holmium:YAG (Ho:YAG) laser is a solid state near infra-red wavelength (2.1 microns) low power energy source. It is the most versatile laser platform available to medical professionals today. As a surgical tool, Ho:YAG has evolved as the laser of choice across a wide variety of medical specialties including orthopedics, urology, ENT, gynecology, gastroenterology and cardiac surgery. The fiberoptic delivery of the Ho:YAG laser makes available the minimally invasive delivery of the prescribed energy to the surgical site via ports or small incisions.
The fiberoptic delivery capability of the Ho:YAG laser provides several clinical advantages when performing TMR, including: laser channeling on a beating or stopped heart (does not require ECG synchronization); transesophageal echocardiogram not required to confirm channel transmurality; fiberoptic delivery for reduced surgical incisions and related morbidity; and thermoacoustic tissue effect to initiate angiogenic response.1,2,3
The CardioGenesis PEARL 5.0 Robotic Handpiece delivery system is designed for delivery through a 5mm port. It is compatible with the Intuitive da Vinci surgical robot for performing TMR through small ports. While a standard stand-alone procedure is performed through a left anterior thoracotomy, the PEARL 5.0 can be used to further reduce the surgical incision and related morbidity.
The mechanism of action for TMR is likely multifactorial. There can be an immediate effect due to surgical denervation.4 It is believed that the significant patient benefit now documented beyond 5 years is related to the angiogenesis that is created in the tissue surrounding the laser channels.5
The clinical benefits of TMR have been shown to be durable for more than 5 years in follow up to prospective, randomized controlled trials.6,7,8
The Instruction for Use (IFU) warns of an increased operative mortality in unstable angina patients (defined as unweanable from intravenous anti-anginal medications ).
Contact customer service through the form below or call 770-419-3355 with any question you may have.
- Atluri P, et al. J Thorac Cardiovasc Surg 2008;135:283-291.
- Lu C, et al. Chin Med J 1999;36:614-618.
- Hughes GC, et al. Ann Thorac Surg 2000;70:504-509.
- Beek JF, et al. J Thorac Cardiovasc Surg 2004;127:517-524.
- Allen KB, et al. Aneshtesiology Clin 2008;26:501-519.
- Allen KB, et al. Ann Thorac Surg 2004;77:1228-1234.
- Aaberge L, et al. J Am Coll Cardiol 2002;39:1588-1593.
- Horvath KA, et al. Circulation 2001;104;I-81-I-84.